ReviewCancers2019

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and

Denis M Collins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.